Spoken Alpha
Immunocore Holdings plc
Immunocore Holdings plc designs immunomodulating medicines using its proprietary ImmTAX platform to treat cancer, infectious diseases, and autoimmune conditions. The company's lead product, KIMMTRAK, is approved in 39 countries for uveal melanoma and is commercially available in 30 countries.
Immunocore Holdings plc is a Healthcare company operating in Biotechnology with a $1.73B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
9 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMCR.
$ curl https://api.spokenalpha.com/v1/companies/IMCRFAQ
Spoken Alpha indexes IMCR's earnings call transcripts at https://spokenalpha.com/companies/IMCR. Each call links to attributed speakers and parsed analyst Q&A. Immunocore Holdings plc's own investor relations page is at https://www.immunocore.com/investors.
Immunocore Holdings plc (IMCR) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
Immunocore Holdings plc (IMCR) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.10 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.02 | $-0.01 | -100.0% | $115.9M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $0.25 | $-0.26 | +100.0% | $106.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-03 | $-0.60 | $-0.20 | -100.0% | $77.4M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.00 | $-0.24 | +98.5% | $103.7M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.20 | $-0.21 | +4.8% | $98.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.10 | $-0.40 | +100.0% | $93.9M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.37 | $-0.16 | -100.0% | $84.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.17 | $-0.34 | +100.0% | $80.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.23 | $-0.52 | +55.8% | $75.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.49 | $-0.38 | -28.9% | $70.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-32.22 | $-21.74 | -48.2% | $56.0M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $0.05 | $-0.36 | +100.0% | $53.6M | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.37 | $-0.40 | +7.5% | $47.2M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.44 | $-0.41 | -7.3% | $44.2M | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-54.00 | $0.03 | -100.0% | $48.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-17 | $0.14 | $-0.37 | +100.0% | $48.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.17 | $-0.62 | +72.6% | $40.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.46 | $-1.05 | +56.2% | $22.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-91.00 | $-82.21 | -10.7% | $6.6M | — | — | EODHD |
Source: EODHD. IMCR reported actuals as published; sparse fields render as —.